Discussion in 'Stocks' started by stonedinvestor, May 14, 2008.

  1. Ok stk number two and I think I'm going to let it go after this.... GLUU mobile is right on the cusp... but we all know about HOLX spending is down at hospitals and digital mammograms are slowing assimilation problems with big purchase pap smears not what they used to be etc.... what it all adds up to is a great growth stk on sale. Twice before I remembeber big 25% clips and the stk went on to new highs and splits.... will it happen again.... ?
    undefined undefined | S&P Marketscope

    9:43 AM ET 5/14/08
    Symbol Last % Chg
    21.65 0.32%
    Real time quote.

    SNPMarketScopeViewsNews2008-05-01 14:37:16.000HOLXHOLOGIC, INC.Barney BrodieHOLX POSTS $0.22 Q2 EPS. OPPENHEIMER SAYS SELL-OFF OVERDONEAnalyst Amit Hazan believes HOLX stock's sell-off overdone, he would be buyer. Says key focus for investors heading into Q2 was Selenia, which beat expectations on both orders and installs once again. Key concerns, as he sees them now, are NovaSure weakness, Pap volume, gross margin. Notes while he's clearly concerned with rate of slowdown in Nova biz, even flat growth in it for next two years would only impact his EPS estimate by less than $0.05. Says Nova comprises only 13% of $1.7B in sales expected for FY 08 (Sep). Says gross margin was not stronger in Q2 because of NovaSure; Pap biz remains stable. Maintains outperform, has $39.50

    and... Recommendations story about HOLX from Citigroup
    Citigroup believes the upcoming Tomosynthesis approval in the second half of 2008 is a meaningful positive catalyst and reiterates a Buy rating on the stock.
  2. Hologic rises after chairman leaves; analyst lifts estimates

    NEW YORK (AP) - Shares of medical technology company Hologic Inc. rose Wednesday after the its chairman resigned in a move that analysts say advances Hologic's integration with Cytyc Corp.

    Chairman Patrick Sullivan resigned Tuesday, and will be replaced by Chief Executive Jack Cumming. Sullivan was the president, chairman and CEO of Cytyc, a medical device maker Hologic bought last year.

    Canaccord Adams analyst Matthew Scalo said the move shows Hologic has finished integrating Cytyc Corp., which it bought last year in a $6.2 billion cash-and-stock deal. Bruce Jackson of RBC Capital Markets said Sullivan's departure gives more freedom to the remaining management of the combined company.

    Leerink Swann & Co. analyst Isaac Ro raised his fiscal 2009 profit and revenue estimates for Hologic, based on the expectation that medical tests using Hologic's NovaSure will increase. He said Novasure is used in more than 70 percent of endometrial ablation procedures, and he expects it to keep that market share for the next year.

    Endometrial ablations are procedures in which part of the uterine lining is destroyed to control heavy bleeding. The procedure is considered an alternative to having a hysterectomy.

    Analyst Ro thinks the company will earn $1.41 per share in the year ending September 2009, on $1.86 billion in revenue. On average, Thomson Financial reports that analysts expect a profit of $1.41 per share on $1.92 billion in revenue.
  3. What do you think guys?

    12% not bad I know I talk a lot of crap about one year holds but I'm bored already... I've got other things bustin out.... Do we sell? ~stoney